PRESS RELEASE

02.26.2015

EPIC SCIENCES TO PRESENT AT 35TH ANNUAL COWEN AND COMPANY HEALTH CARE CONFERENCE.

LinkedIn
Twitter
Follow by Email

Epic’s circulating tumor cell analysis provides comprehensive, real-time information from a liquid biopsy that could help guide cancer treatment.

Epic Sciences announced today that president and CEO Murali Prahalad, Ph.D. will present at the 35th Annual Cowen and Company Health Care Conference on Wednesday, March 4, 2015 at 10:00 a.m. EST in the MIT Room, 3rd Floor. The conference will be held at the Boston Marriott Copley Place Hotel in Boston, Mass.

Epic is developing diagnostic tests of high clinical utility to deliver real-time detection of genomic and proteomic changes that occur during the course of cancer treatments. From a simple blood test, Epic’s “no cell left behind” technology applies a global, unbiased approach to analyze all possible types of circulating tumor cells to match patients to singular or combination therapies or monitor and understand drug resistance.

About Epic Sciences

At Epic Sciences, we develop clinically proven predictive tests to detect and monitor cancer at the individual cell level. With a proprietary rare-cell detection engine, we provide insights to clinical, biotech, pharmaceutical and academic teams on how cancer emerges, mutates and remits so they can make pivotal decisions at every point in patient treatment with greater certainty. Recognizing the unique nature of each person’s cancer, we offer truly personalized diagnostic tests, while being non-invasive for the patient.

We have developed the first clinically proven predictive test for metastatic castration-resistant prostrate cancer (mCRPC), the Epic AR-V7 test. Using the same rare-cell detection platform and Epic’s biobank of over 30,000 blood samples, each profiled with predictive biomarkers, we partner with leading pharmaceutical and biotechnology companies, major cancer centers, the National Cancer Institute (NCI), and the National Institutes of Health (NIH) to pursue additional predictive tests for breast, ovarian, colon and other cancers and diseases. Our mission is to revolutionize cancer care and therapies to make them as precise, safe and life-sustaining as humanly possible.

For more information, visit epicsciences.com.

Stay in touch on LinkedIn, on Twitter@EpicSciences and Facebook.com/EpicSciences.

Epic Sciences Media Contact: Jessica Yingling, Ph.D., Little Dog Communications Inc., jessica@litldog.com,+1.858.344.8091